Related Experiment Video
Updated: May 20, 2025
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
Proteomic Biomarker Panel for Gauging Multiple Sclerosis Disease Activity: A Case Series From Real-World Use
Taylor Gonyou1, Patricia Izbicki2, Jim Eubanks2
1From the Michigan Institute for Neurological Disorders, Farmington Hills, MI.
Background:
Advances in serum proteomics have provided more precise tools for the characterization of multiple sclerosis (MS) and enabled enhanced clinical management of the disease. The multivariate proteomic Multiple Sclerosis Disease Activity (MSDA) test has been analytically and clinically validated.
Methods:
This is a single-center retrospective case series. Four women with MS were monitored between 2022 and 2023 with up to 2 MSDA time points. Their full clinical histories and exams, along with treatment and MRI changes, were collected with the MSDA tests.
Results:
Patients' baseline and follow-up MSDA scores were consistent with disease activity, treatment response, and disease stability.
Conclusions:
We provide a real-world case series to show that MSDA could help to determine MS disease activity at baseline and throughout the disease course. MSDA could help to differentiate clinically stable vs active patients to monitor DMT treatment response.
